Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBBNX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļBeta Bionics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 30, 2025
āļāļĩāļāļĩāđāļSaint (Sean)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ291
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJan 30
āļāļĩāđāļāļĒāļđāđ11 Hughes
āđāļĄāļ·āļāļIRVINE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92618
āđāļāļĢāļĻāļąāļāļāđ19494277785
āđāļ§āđāļāđāļāļāđhttps://www.betabionics.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBBNX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 30, 2025
āļāļĩāļāļĩāđāļSaint (Sean)
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Ms. Christy Jones
Independent Director
Mr. Gerard J. Michel
Independent Director
Mr. Sean D. Carney
Independent Director
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Maria Palasis, Ph.D.
Independent Director
Mr. Blake Beber
Investor Relations
Mr. Sean Saint
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Dan Dearen
Independent Director
Mr. Stephen Feider
Chief Financial Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Ms. Christy Jones
Independent Director
Mr. Gerard J. Michel
Independent Director
Mr. Sean D. Carney
Independent Director
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Maria Palasis, Ph.D.
Independent Director
State Street SPDR S&P Health Care Equipment ETF
Invesco Dorsey Wright Healthcare Momentum ETF
First Trust Nasdaq Lux Digi Health Solutions ETF
Global X Internet of Things ETF
iShares U.S. Medical Devices ETF
Goldman Sachs Innovate Equity ETF
iShares Russell 2000 Growth ETF
ProShares Hedge Replication ETF
Proshares Ultra Russell 2000
Global X Russell 2000 ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
State Street SPDR S&P Health Care Equipment ETF
āļŠāļąāļāļŠāđāļ§āļ1.33%
Invesco Dorsey Wright Healthcare Momentum ETF
āļŠāļąāļāļŠāđāļ§āļ0.77%
First Trust Nasdaq Lux Digi Health Solutions ETF
āļŠāļąāļāļŠāđāļ§āļ0.58%
Global X Internet of Things ETF
āļŠāļąāļāļŠāđāļ§āļ0.47%
iShares U.S. Medical Devices ETF
āļŠāļąāļāļŠāđāļ§āļ0.13%
Goldman Sachs Innovate Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.08%
iShares Russell 2000 Growth ETF
āļŠāļąāļāļŠāđāļ§āļ0.05%
ProShares Hedge Replication ETF
āļŠāļąāļāļŠāđāļ§āļ0.05%
Proshares Ultra Russell 2000
āļŠāļąāļāļŠāđāļ§āļ0.04%
Global X Russell 2000 ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ